Alendronic Acid 35 mg (Generic)

Product Overview

Alendronic Acid 35 mg (Generic) is a bisphosphonate medication manufactured by Cipla Limited. It is indicated for the treatment of osteoporosis in post‑menopausal women and men who are at increased risk of bone fractures. The product is supplied in a convenient strip containing four tablets, each delivering 35 mg of the active ingredient. Pack sizes of 28, 56, and 84 tablets are available, providing flexible options for long‑term therapy.

What is Alendronate 35 mg (Generic)

Alendronate sodium, commonly referred to as alendronic acid, belongs to a class of drugs known as nitrogen‑containing bisphosphonates. These agents bind strongly to hydroxyapatite in bone tissue and inhibit the activity of osteoclasts, the cells responsible for bone resorption. By reducing bone loss, alendronate helps maintain or modestly increase bone mineral density (BMD), thereby lowering the risk of vertebral and non‑vertebral fractures.

Uses and Benefits

The primary use of Alendronate 35 mg is the prevention and treatment of osteoporosis. Clinical studies have demonstrated that regular use of alendronate can reduce the incidence of hip and vertebral fractures by up to 50 % in high‑risk populations. In addition to fracture prevention, patients often experience stabilization of bone density scores after six months to one year of therapy. The medication is also used off‑label for the management of glucocorticoid‑induced osteoporosis, a condition that arises in patients receiving long‑term corticosteroid treatment.

How It Works

Alendronate is a stable, nitrogen‑containing bisphosphonate that is orally administered and rapidly absorbed in the upper part of the gastrointestinal tract. Once absorbed, it travels to sites of active bone remodeling, where it binds to the bone matrix. In osteoclasts, alendronate interferes with the mevalonate pathway, leading to apoptosis of these resorption cells. This mechanism reduces the rate of bone turnover, allowing bone formation to outpace resorption, which ultimately improves bone strength.

Dosage Guidelines

Patients should take one tablet of Alendronate 35 mg once weekly, preferably on an empty stomach. The tablet must be swallowed whole with a full glass of plain water, and the patient should remain upright for at least 30 minutes after dosing to minimize esophageal irritation. It is important to avoid taking the medication with food, other beverages, or other medications, including calcium supplements, antacids, or iron, as these can reduce absorption. Dosage may be adjusted based on renal function, and patients with severe renal impairment should consult a healthcare professional before use.

Side Effects

Like all pharmaceuticals, Alendronate can cause adverse effects. The most commonly reported side effects include gastrointestinal discomfort such as heartburn, nausea, and abdominal pain. More serious, though less frequent, events may involve esophageal irritation, ulceration, or rare cases of osteonecrosis of the jaw (ONJ). Patients should seek immediate medical attention if they experience severe chest pain, difficulty swallowing, or persistent jaw swelling. Most side effects are mild and often diminish with continued use.

Warnings and Precautions

Before initiating therapy, clinicians should evaluate patients for conditions that may contraindicate bisphosphonate use, such as hypocalcemia, severe renal impairment, or inability to remain upright for 30 minutes post‑dose. Patients should be advised to report any new dental problems, as ONJ has been reported in a small subset of individuals receiving high‑dose intravenous bisphosphonates, though the risk with oral alendronate is low. Pregnant or breastfeeding women should avoid this medication unless the benefits clearly outweigh the risks. For comprehensive prescribing information, refer to the FDA label here.

Frequently Asked Questions

1. How long does it take to see an increase in bone density?

Clinical trials show measurable improvements in bone mineral density after 6 to 12 months of consistent weekly dosing. The degree of increase varies by individual and baseline BMD.

2. Can I take Alendronate with vitamin D supplements?

Yes. Vitamin D and calcium supplements are often recommended as adjunct therapy to support bone health, but they should be taken at a different time of day to avoid interference with absorption.

3. Is it safe to use during dental procedures?

Most dental procedures are safe, but patients should inform their dentist about bisphosphonate use. If invasive dental work is planned, a brief pause in therapy may be considered after discussing risks with the prescribing physician.

4. What should I do if I miss a dose?

If a weekly dose is missed, the patient should take it as soon as remembered, provided at least 7 days have passed since the previous dose. If less than 7 days remain, the missed dose should be skipped and the regular schedule resumed.

5. Are there any drug interactions I should be aware of?

Alendronate may interact with medications that contain calcium, magnesium, iron, or aluminum, as these can reduce its absorption. Additionally, certain antacids and supplements should be taken at least 30 minutes after the bisphosphonate. Always review your medication list with a healthcare professional.

For additional details about osteoporosis management and bisphosphonate therapy, reputable sources such as the National Institutes of Health (NIH) osteoporosis page and MedlinePlus offer comprehensive guidance.

Related Products

• Ciplox 750mg (Ciprofloxacin)
• Diclofenac SR 100 mg
• Reactin 50 mg (Diclofenac)
• Cromal Forte Eye Drop (Sodium Cromoglycate)
• Rizact 5 mg (Rizatriptan)
• Flunarizine 5 mg (Generic)
• Warf 1 mg (Warfarin)
• Warf 2 mg (Warfarin)
• Warf 3 mg (Warfarin)
• Mucinac 200 mg (Acetylcysteine)
• Temozolomide 20 mg (Generic)
• Prandial 0.3 MD (Voglibose)